Growth hormone treatment in 35 prepubertal children with achondroplasia: A five-year dose-response trial
(2005) In Acta Pædiatrica 94(10). p.1402-1410- Abstract
- Background: Achondroplasia is a skeletal dysplasia with extreme, disproportionate, short stature. Aim: In a 5-y growth hormone (GH) treatment study including 1 y without treatment, we investigated growth and body proportion response in 35 children with achondroplasia. Methods: Patients were randomized to either 0.1 IU/kg (n=18) or 0.2 IU/kg (n=17) per day. GH treatment was interrupted for 12 mo after 2 y of treatment in prepubertal patients to study catch-down growth. Mean height SDS (HSDS) at start was -5.6 and -5.2 for the low- and high-dose groups, respectively, and mean age 7.3 and 6.6 y. Results: Mean growth velocity (baseline 4.5/4.6 cm/y for the groups) increased significantly by 1.9/3.6 cm/y during the first year and by 0.5/1.5... (More)
- Background: Achondroplasia is a skeletal dysplasia with extreme, disproportionate, short stature. Aim: In a 5-y growth hormone (GH) treatment study including 1 y without treatment, we investigated growth and body proportion response in 35 children with achondroplasia. Methods: Patients were randomized to either 0.1 IU/kg (n=18) or 0.2 IU/kg (n=17) per day. GH treatment was interrupted for 12 mo after 2 y of treatment in prepubertal patients to study catch-down growth. Mean height SDS (HSDS) at start was -5.6 and -5.2 for the low- and high-dose groups, respectively, and mean age 7.3 and 6.6 y. Results: Mean growth velocity (baseline 4.5/4.6 cm/y for the groups) increased significantly by 1.9/3.6 cm/y during the first year and by 0.5/1.5 cm/y during the second year. During the third year, a decrease of growth velocity was observed at 1.9/1.3 cm/y below baseline values. HSDS increased significantly by 0.6/0.8 during the first year of treatment and in total by 1.3/1.6 during the 5 y of study. Sitting height SDS improved significantly from -2.1/-1.7 to -0.8/0.2 during the study. Body proportion (sitting height/total height) or arm span did not show any significant change. Conclusion: GH treatment of children with achondroplasia improves height during 4 y of therapy without adverse effect on trunk-leg disproportion. The short-term effect is comparable to that reported in Turner and Noonan syndrome and in idiopathic short stature. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/898791
- author
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- skeletal dysplasia, achondroplasia, growth hormone treatment
- in
- Acta Pædiatrica
- volume
- 94
- issue
- 10
- pages
- 1402 - 1410
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:16299871
- wos:000232931900010
- scopus:27144547212
- ISSN
- 1651-2227
- DOI
- 10.1111/j.1651-2227.2005.tb01811.x
- language
- English
- LU publication?
- yes
- id
- 40258df6-8379-4b4a-b38c-096b74416106 (old id 898791)
- date added to LUP
- 2016-04-01 15:38:41
- date last changed
- 2022-03-07 00:41:08
@article{40258df6-8379-4b4a-b38c-096b74416106, abstract = {{Background: Achondroplasia is a skeletal dysplasia with extreme, disproportionate, short stature. Aim: In a 5-y growth hormone (GH) treatment study including 1 y without treatment, we investigated growth and body proportion response in 35 children with achondroplasia. Methods: Patients were randomized to either 0.1 IU/kg (n=18) or 0.2 IU/kg (n=17) per day. GH treatment was interrupted for 12 mo after 2 y of treatment in prepubertal patients to study catch-down growth. Mean height SDS (HSDS) at start was -5.6 and -5.2 for the low- and high-dose groups, respectively, and mean age 7.3 and 6.6 y. Results: Mean growth velocity (baseline 4.5/4.6 cm/y for the groups) increased significantly by 1.9/3.6 cm/y during the first year and by 0.5/1.5 cm/y during the second year. During the third year, a decrease of growth velocity was observed at 1.9/1.3 cm/y below baseline values. HSDS increased significantly by 0.6/0.8 during the first year of treatment and in total by 1.3/1.6 during the 5 y of study. Sitting height SDS improved significantly from -2.1/-1.7 to -0.8/0.2 during the study. Body proportion (sitting height/total height) or arm span did not show any significant change. Conclusion: GH treatment of children with achondroplasia improves height during 4 y of therapy without adverse effect on trunk-leg disproportion. The short-term effect is comparable to that reported in Turner and Noonan syndrome and in idiopathic short stature.}}, author = {{Hertel, N T and Eklof, O and Ivarsson, Sten and Aronson, S and Westphal, O and Sipila, I and Kaitila, I and Bland, J and Veimo, D and Muller, J and Mohnike, K and Neumeyer, L and Ritzen, M and Hagenas, L}}, issn = {{1651-2227}}, keywords = {{skeletal dysplasia; achondroplasia; growth hormone treatment}}, language = {{eng}}, number = {{10}}, pages = {{1402--1410}}, publisher = {{Wiley-Blackwell}}, series = {{Acta Pædiatrica}}, title = {{Growth hormone treatment in 35 prepubertal children with achondroplasia: A five-year dose-response trial}}, url = {{http://dx.doi.org/10.1111/j.1651-2227.2005.tb01811.x}}, doi = {{10.1111/j.1651-2227.2005.tb01811.x}}, volume = {{94}}, year = {{2005}}, }